|
|
 |
|
-
2025 Estimated Capital Gain Distributions
Certain First Trust First Trust Exchange-Traded Funds are expected to pay a long-term capital gain distribution in December. For a list of exchange-traded funds expected to pay a long-term capital gain distribution, please click here. Also, certain First Trust Exchange-Traded Funds are expected to pay short-term capital gain distributions in December. For a list of exchange-traded funds expected to pay a short-term capital gain distribution, please click here. Final determination of the source and tax status of all distributions paid in the current year are to be made after year-end and could differ from the expectations noted above.
Investment Objective/Strategy - The First Trust Nasdaq Lux Digital Health Solutions ETF (the "Fund") seeks investment results that correspond generally to the price and yield (before the Fund's fees and expenses) of an equity index called the Nasdaq Lux Health Tech™ Index (the "Index"). The Fund will normally invest at least 80% of its net assets (plus any borrowings for investment purposes) in the common stocks and depositary receipts that comprise the Index.
There can be no assurance that the Fund's investment objectives will be achieved.
- The Nasdaq Lux Health Tech™ Index (the "index") is designed to measure the performance of a selection of companies that are primarily engaged in and involved at the intersection of healthcare and technology ("Digital Health Companies"). The index begins with a universe of common stocks and depositary receipts of companies listed on an index-eligible global stock exchange by issuers classified by Lux Capital as Digital Health Companies.
- Each security must have a minimum free float market capitalization of $500 million and a 3-month average daily trading volume of at least $3 million.
- In order to remain in the index, companies must have at least 7% revenue growth in one of the two preceding years or a market capitalization of at least $50 billion.
- Companies added to the index during reconstitutions must have annual revenue growth of at least 10% in each of the two preceding full fiscal years.
- Securities selected for the index are weighted according to a modified market capitalization methodology.
- Under this methodology, the weighting of each security is determined by dividing its free float market capitalization by the aggregate free float market capitalization of all the securities in the index subject to a maximum weighting of 8%.
- These weights are maintained for the five securities with the largest free float market capitalization, and all other securities in the index are subject to a maximum weighting of 4%.
- No security may be weighted above 8% and only five securities may exceed 4%.
- The index is rebalanced and reconstituted semi-annually.
| Ticker | EKG |
| Fund Type | Health Care |
| Investment Advisor | First Trust Advisors L.P. |
| Investor Servicing Agent | Bank of New York Mellon Corp |
| CUSIP | 33719L106 |
| ISIN | US33719L1061 |
| Intraday NAV | EKGIV |
| Fiscal Year-End | 09/30 |
| Exchange | Nasdaq |
| Inception | 3/22/2022 |
| Inception Price | $20.44 |
| Inception NAV | $20.44 |
| Rebalance Frequency | Semi-Annual |
| Total Expense Ratio* | 0.65% |
* As of 2/3/2025
| Closing NAV1 | $19.66 |
| Closing Market Price2 | $19.64 |
| Bid/Ask Midpoint | $19.65 |
| Bid/Ask Discount | 0.08% |
| 30-Day Median Bid/Ask Spread3 | 0.30% |
| Total Net Assets | $2,948,612 |
| Outstanding Shares | 150,002 |
| Daily Volume | 1 |
| Average 30-Day Daily Volume | 1,493 |
| Closing Market Price 52-Week High/Low | $19.89 / $14.16 |
| Closing NAV 52-Week High/Low | $19.89 / $14.19 |
| Number of Holdings (excluding cash) | 38 |
| Holding |
Percent |
| Intuitive Surgical, Inc. |
8.62% |
| IQVIA Holdings Inc. |
8.39% |
| ResMed Inc. |
6.62% |
| Veeva Systems Inc. (Class A) |
6.37% |
| Exact Sciences Corporation |
6.19% |
| DexCom, Inc. |
6.16% |
| Natera, Inc. |
5.15% |
| Guardant Health, Inc. |
5.01% |
| Illumina, Inc. |
4.57% |
| Hologic, Inc. |
3.96% |
*Â Excluding cash.Â
Holdings are subject to change.
Past performance is not indicative of future results.
| Maximum Market Cap. | $203,296 |
| Median Market Cap. | $4,875 |
| Minimum Market Cap. | $1,294 |
| Price/Earnings | 37.10 |
| Price/Book | 5.77 |
| Price/Cash Flow | 27.47 |
| Price/Sales | 4.25 |
| Country |
Percent |
| United States |
95.55% |
| The Netherlands |
3.58% |
| Costa Rica |
0.87% |
|
|
2024 |
Q1 2025 |
Q2 2025 |
Q3 2025 |
| Days Traded at Premium |
127 |
36 |
10 |
7 |
| Days Traded at Discount |
125 |
24 |
52 |
57 |
|
Medical Equipment and Services
|
56.70%
|
|
Health Care Providers
|
22.62%
|
|
Pharmaceuticals and Biotechnology
|
18.93%
|
|
Life Insurance
|
1.40%
|
|
Software and Computer Services
|
0.35%
|
|
|
Tracking Index: Nasdaq Lux Health Tech™ Index
| |
Standard Deviation |
Alpha |
Beta |
Sharpe Ratio |
Correlation |
| EKG |
24.09% |
1.72 |
1.12 |
0.16 |
0.62 |
| S&P Composite 1500® Health Care Index |
13.46% |
--- |
1.00 |
0.14 |
1.00 |
Standard Deviation is a measure of price variability (risk). Alpha is an indication of how much an investment outperforms or underperforms
on a risk-adjusted basis relative to its benchmark.Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure
of excess reward per unit of volatility. Correlation is a measure of the similarity of performance.
Russell 3000® Index - The Index is comprised of the 3000 largest and most liquid stocks based and traded in the U.S. S&P Composite 1500® Health Care Index - The Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|